Related Experiment Video
Updated: Apr 13, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Programmed cell death-1 inhibition in lymphoma.
Eliza A Hawkes1, Andrew Grigg2, Geoff Chong3
1Department of Medical Oncology and Clinical Haematology, Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, Australia; Department of Medical Oncology, Eastern Health, Melbourne, VIC Australia; Monash University, Melbourne, VIC, Australia.
Programmed cell death-1 (PD-1) inhibitors show promise in treating lymphoma by blocking immune evasion. This review covers the PD-1 pathway
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cancers evade immune surveillance by upregulating inhibitory signals like PD-1.
- Anti-PD-1 monoclonal antibodies restore anti-tumor immunity.
- PD-1 pathway complexity in lymphoma, a malignancy of immune cells, is under investigation.
Purpose of the Study:
- To review the role of the PD-1 pathway in lymphoma.
- To assess clinical data for PD-1 inhibitors in lymphoma.
- To discuss future strategies for PD-1 based therapies in lymphoma.
Main Methods:
- Literature review of scientific articles on the PD-1 pathway in lymphoma.
- Analysis of clinical trial data for PD-1 inhibitors in relapsed lymphoma subtypes.
- Synthesis of current knowledge and future directions for PD-1 targeted agents.
Main Results:
- PD-1 pathway plays a complex role in lymphoma.
- Early clinical trials demonstrate significant activity of PD-1 inhibitors in relapsed lymphoma.
- PD-1 inhibitors represent a promising next-generation therapy for lymphoma.
Conclusions:
- PD-1 inhibitors are effective in treating various lymphoma subtypes.
- Further research into the PD-1 pathway can optimize lymphoma treatment.
- PD-1 targeted agents offer a new frontier in immuno-oncology for lymphoma.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Inhibition of Cdk Activity
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...